Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(LY 341495; LY-341495)
LY341495 Chemical Structure
|Product name: LY341495|
|Cat. No.: HY-70059|
LY341495 is a highly potent and selective group II metabotropic glutamate receptor antagonist. (Ki/IC50 values are 2.3, 1.3, 173, 990, 6800, 8200 and 22000 nM for human mGlu2, mGlu3, mGlu8 , mGlu7a, mGlu1a, mGlu5a and mGlu4a receptors respectively).
IC50 Value: 2.9 nM (for mGluR-2, human); 10 nM (for mGluR-3, human); 170 nM (for mGluR-8, huma)
in vitro: LY341495 was micromolar potent in antagonizing quisqualate-induced phosphoinositide (PI) hydrolysis, with IC50 values of 7.8 and 8.2 microM for mGlu1a and mGlu5a receptors, respectively. Among the human group III mGlu receptors, the most potent inhibition of L-2-amino-4-phosphonobutyric acid (L-AP4) responses was seen for LY341495 at mGlu8, with an IC50 of 0.17 microM. LY341495 was less potent at mGlu7 (IC50 = 0.99 microM) and least potent at mGlu4 (IC50 = 22 microM). LY341495 competitively antagonised DHPG-stimulated PI hydrolysis in AV12-664 cells expressing either human mGlu1 or mGlu5 receptors with Ki-values of 7.0 and 7.6 microM, respectively.
in vivo: LY341495 (3 mg/kg, i.p., 2.5 h) -induced c-Fos expression was not altered in either KO brain. However, in mGluR3-KO mice, LY341495 was almost inactive in the central extended amygdala [central nucleus of the amygdala, lateral (CeL) and bed nucleus of the stria terminalis, laterodorsal (BSTLD)].
|M.Wt||353.37||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.8299 mL||14.1495 mL||28.2990 mL|
|5 mM||0.5660 mL||2.8299 mL||5.6598 mL|
|10 mM||0.2830 mL||1.4149 mL||2.8299 mL|
. Linden AM, et al. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495.Neuropharmacology. 2009 Aug;57(2):172-82. Epub 2009 May 27.
. Bespalov AY, et al. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.Eur J Pharmacol. 2008 Sep 11;592(1-3):96-102. Epub 2008 Jul 2.
. Ornstein, P.L, et al., 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. J Med Chem, 1998. 41(3): p. 358-78.
ADX-47273 is a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5(EC50=170 nM).
CPPHA is a selective positive allosteric modulator of mGluR5 receptor.
CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM.
Dipraglurant (ADX 48621) is a mGluR5 antagonists with IC50 of 0.021 (mu)M.
JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.
L-Glutamine is a non-essential amino acid present abundantly throughout the body and is involved in gastrointestinal disorders.
LY2979165 is a mGlu2 agonist, which is a novel potent agent that is used as anti-depressants.
LY354740 is a highly potent, efficacious and selective group II (mGlu2/3) receptor agonist, produces >90% suppression of forskolin-stimulated cAMP formation with an EC50 of 5.1 (plusmn) 0.3 nM.
LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor.
Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5.